A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

NCT05391061 · tracked via the Priya Life Science South Korea tracker

Sponsor

Pfizer

Phase

Observational

Started

2023-01-07

Last updated

2025-12-09

Condition(s) studied

Dermatitis, Atopic

Investigational drug(s) / intervention(s)

Abrocitinib →

Abrocitinib: Tablets

Study summary

The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD).

AD is a long-lasting itchy red rash, caused by a skin reaction.

This study is seeking participants who:

1. Are patients with moderate to severe AD who have been waiting to start treatment with Cibinqo
2. Have evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s) or legal guardian, have been informed of all important details of the study Investigators will collect and record the information on each participant's experiences with Cibinqo. This study medicine is a tablet which is taken by mouth. Participants will be observed for about a year. During this time, we will study the experiences of people receiving the study medicine to help us decide if the study medicine is safe and effective.

Eligibility

Sex

ALL

Min age

12 Years

Max age

—

Healthy volunteers

This study is seeking participants who should meet the usual prescribing criteria for Cibinqo® Tablets as per the Local Product Document (LPD) and should be entered into the study at the physician's discretion. Inclusion Criteria: 1. Patients with moderate to severe AD who have been determined to start treatment with Cibinqo Tablet according to the approved indications of the medicinal product. • Atopic Dermatitis Cibinqo Tablet is indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis who have required systemic therapies. 2. Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study Exclusion Criteria: 1. Patients who have previously received Cibinqo Tablet 2. Patients concurrently participating in other studies involving therapeutic interventions and/or investigational products 3. Patients who have contraindications to Cibinqo Tablet as specified in the approved LPD • Contraindications to Cibinqo Tablet * Patients with platelet count \<150 × 103/mm3, an absolute neutrophil count (ANC) \<1 × 103/mm3, an absolute lymphocyte count (ALC) \<0.5 × 103/mm3 or who have a haemoglobin value \<8 g/dL * Hypersensitivity to the active substance or to any of the excipients * Active serious systemic infetions, including tuberculosis(TB) * Severe hepatic impairment * Pregnancy and breast-feeding * Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

Primary outcome measure(s)

Number of participants with Adverse Events (AE's) according to frequency — Up to 52 weeks from the time of first treatment
Number of participants with Adverse Drug Reactions (ADR's) according to frequency — up to 52 weeks from the time of first treatment
Number of participants with unexpected AE's according to frequency — up to 52 weeks from the time of first treatment
Number of participants with unexpected ADR's according to frequency — up to 52 weeks from the time of first treatment
Number of participants with Serious Adverse Events (SAE's) according to frequency — up to 52 weeks from the time of first treatment
Number of participants with Serious Adverse Drug Reactions (SADR's) according to frequency — up to 52 weeks from the time of first treatment
Number of participants with Adverse Events of Special Interest (AESI) according to frequency — up to 52 weeks from the time of first treatment

Trial sites (1)

Facility	City	Region	Status
Pfizer Tower	Seoul	South Korea	Recruiting

More Pfizer trials in South Korea

Korea Comirnaty Post-marketing Surveillance Active, not recruiting

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market Recruiting

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). Active, not recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors Recruiting

Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone Active, not recruiting

Other trials for the same condition

Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05391061 on ClinicalTrials.gov ↗ ← All trials in South Korea